Company news
Kala Bio, Inc. news in 2021
Kala Bio, Inc.'s news releases, calls and decks from 2021, newest first.
Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 17, 2021
Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 14, 2021
Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call
November 14, 2021
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases
November 14, 2021
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in November 2021
November 10, 2021
Kala Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call
November 7, 2021
Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors
October 17, 2021
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
September 6, 2021
Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 4, 2021
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August
August 3, 2021
Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call
July 28, 2021
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
June 2, 2021
Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference
May 26, 2021
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
May 5, 2021
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 4, 2021
Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
April 27, 2021
Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
March 15, 2021
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
February 24, 2021
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
February 17, 2021
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts
February 15, 2021
Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline
January 6, 2021